Trial Profile
A randomized, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2021
Price :
$35
*
At a glance
- Drugs MLN 3897 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Millennium
- 01 Dec 2010 Results published in Arthritis and Rheumatism.
- 31 Jan 2010 Status changed from active, no longer recruiting to completed.
- 10 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by Netherlands Trial Register.